Should Aspirin Be the Second-Line Antiplatelet in CAD?
From European Society of Cardiology 2022, Drs O'Donoghue and Valgimigli discuss the latest analysis suggesting that for single antiplatelet therapy in patients with CAD, P2Y12 inhibitors beat aspirin. https://www.medscape.com/index/section_10388_0
Видео Should Aspirin Be the Second-Line Antiplatelet in CAD? канала Medscape
Видео Should Aspirin Be the Second-Line Antiplatelet in CAD? канала Medscape
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Innovation in Cardiology | Linkedin LIVE
3D Printing of Complex Orthopedic Implants Fills Niche Role
Medscape TV Presents: Colorectal Cancer in Young People, Part I
Hope Is Fine, but Reality Is Best in End-of-Life Care
Cutting Edge Developments in Hereditary Angioedema: Insights Into 2024 EAACI
NEW! Medscape TV Premier: Confronting Insulin
'Remember Why We Went Into This': Balancing the Dark Days in Oncology | ASCO 2019
Adult Vaccines 2022: Who Needs What, and When?
Why Facebook Doesn't Really Help Diagnose Diabetes
MedscapeTV • Dry Eye: A Clinical Focus - Episode 1: An Uncanny Mimic
Monkeypox: What Do Experts Actually Think?
New Pediatric Advanced Life Support Guidelines Raise Questions
Antiseizure Meds and Cardiovascular Risk
MedscapeTV • Going the Distance With Metastatic Breast Cancer - Episode 1: The Journey Begins
Should ADAURA Trial Results Change Practice in NSCLC?
Value of Simulation | Medscape Education
Frontal Lobe Spike, Fake Smiling, Device for DVT | The Week That Wasn't
Top 10 Advances in Thoracic Oncology in 2020
Patient's google searches, learning in your sleep, more anti-vaxers | The Week that Wasn't
Tackling the Tough Questions on TAAR1 in Schizophrenia: A Live Social Media Event